Document is current
Any future updates will be listed below
-
Authors
Speight, Jane https://orcid.org/0000-0002-1204-6896
Hussain, Sufyan https://orcid.org/0000-0001-6611-8245
Anandhakrishnan, Ananthi https://orcid.org/0009-0002-9547-3355
Danne, Thomas
Latres, Esther
Karpen, Stephen R. https://orcid.org/0000-0002-9063-8010
Mytkolli, Linxi
Scibilia, Renza
Soeholm, Uffe
Senior, Peter A. https://orcid.org/0000-0003-1033-8673
,
Adams, Dawn
Ahnstedt, Hilda
Albanese-O’Neill, Anastasia
Berishvili, Ekaterina
Cleal, Bryan
Cooke, Debbie
Dutta, Sanjoy
Ehrmann, Dominic
Forbes, Shareen
Gibson, Kathleen
Greeno, Brianna
Heller, Simon R.
del Pozo, Carmen Hurtado
Jefferson, Stephen
Keighron, Cameron
Lally, Julianne
Marinac, Marjana
McLeod, Heather
Nutt, Dominic
Piemonti, Lorenzo
Pokerznik, Mary Anna
Press, Chanel
Read, Meaghan
de Wit, Maartje
Vallis, Michael
- License Information
-
More Information
Article History
First Online: 18 February 2026
Competing interests
: J.S. is the copyright holder of several PROMs, none of which were discussed explicitly during the PROMISE workshop. J.S. has received unrestricted educational grants from Lilly, Novo Nordisk and Sanofi. J.S., P.A.S. and S.R.H. are members of the Vertex Scientific Advisory Panel and receive honoraria to their respective research groups for their contributions to the Advisory Panel. J.S. and P.A.S. have received grants from JDRF (now known as Breakthrough T1D). P.A.S. has received consulting or personal fees from Abbott, Bayer, Dexcom, Eli Lilly, GSK, Insulet, Novo Nordisk, Sanofi and Vertex. S.H. has served on the advisory board for Tandem, Dexcom, Medtronic, Sanofi and Roche, and undertaken non-promotional educational/or consultancy work for Abbott UK, Insulet, Dexcom, Sanofi, Lilly and Roche; SH’s institution has received research grant support from Abbott and Insulet. E.L., T.D. and S.K. are employees of Breakthrough T1D. E.L. is a former employee of Regeneron Pharmaceuticals and owns company stock. U.S. has previously been employed by Novo Nordisk A/S. L.P. has served on advisory boards for Novo Nordisk, Sanofi, Roche and Vertex. M.V. has served on advisory boards and received lecture fees from Abbott Diabetes Care, Medtronic and Novo Nordisk. S.R.H. has served on advisory boards for Vertex, Eli Lilly, Novo Nordisk, Zealand, Zucara and Medtronic and on data and safety monitoring committees for Eli Lilly, for which his institution has received remuneration. S.F. has served on advisory boards for Sanofi and has received funding and acted as a consultant for the Novo Nordisk Cell Therapy Programme.
